Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220684802> ?p ?o ?g. }
- W4220684802 endingPage "332.e10" @default.
- W4220684802 startingPage "332.e1" @default.
- W4220684802 abstract "Anti-thymocyte globulin (ATG) is often included in the conditioning regimen to prevent graft-versus-host disease (GVHD) in allogeneic hematopoietic cell transplantation (allo-HCT). However, the risk of virus reactivation increases significantly. We conducted a single-center prospective study to identify the optimal ATG exposure that ensures engraftment, effectively prevents acute GVHD, and reduces the risk of virus reactivation without increasing relapse of malignant diseases in haploidentical peripheral blood stem cell transplantation (haplo-PBSCT). From September 2018 to June 2020, 106 patients (median age, 32 years) with malignant hematological diseases who received haplo-PBSCT for the first time were enrolled. All patients received 10 mg/kg rabbit ATG (thymoglobulin) divided for 4 days (days -5 to -2). Pre-transplant, post-transplant, and total areas under the concentration-time curve (AUCs) of active ATG were calculated. Total AUC of active ATG was shown to be the best predictor for virus reactivation and acute GVHD of grades II to IV or grades III and IV. The optimal total AUC range of active ATG was 100 to 148.5 UE/mL/day. The median time was 14 versus 13 days (P = .184) for neutrophil engraftment and 13 versus 13 days (P = .263) for platelet engraftment in the optimal and non-optimal AUC groups, respectively. The optimal AUC group showed a lower cumulative incidence of cytomegalovirus (CMV) reactivation and persistent CMV viremia than the non-optimal AUC group: 60.6% (95% confidence interval [CI], 48.3%-73.1%) versus 77.1% (95% CI, 64.5%-87.7%; P = .016) and 31.5% (95% CI, 21.2%-45.3%) versus 56.3% (95% CI, 42.9%-70.4%; P = .007), respectively. The cumulative incidence of persistent Epstein-Barr virus (EBV) viremia in the optimal AUC group was significantly lower than the non-optimal total AUC group: 33.1% (95% CI, 22.5%-46.8%) versus 52.6% (95% CI, 39.3%-67.2%; P = .048). However, there was no difference in EBV reactivation (P = .752). Similar outcomes were observed for grade II to IV and grade III and IV acute GVHD between the two groups: 48.6% (95% CI, 36.8%-62.0%) versus 37.0% (95% CI, 24.8%-52.5%; P = .113) and 10.4% (95% CI, 4.8%-21.7%) versus 4.2% (95% CI, 1.0%-15.6%; P = .234, respectively. Relapse, non-relapse mortality, and disease-free survival demonstrated no significant differences between the two groups. But, overall survival at 2 years tended to increase in the optimal AUC group: 75.7% (95% CI, 62.4%-84.8%) versus 57.8% (95% CI, 42.4%-70.4%; P = .061). These data support an optimal active ATG exposure of 110 to 148.5 UE/mL/day in haplo-PBSCT. Individualized dosing of ATG in allo-HCT might reduce the risk of virus reactivation and effectively prevent acute GVHD simultaneously." @default.
- W4220684802 created "2022-04-03" @default.
- W4220684802 creator A5005228021 @default.
- W4220684802 creator A5007161525 @default.
- W4220684802 creator A5007172784 @default.
- W4220684802 creator A5010465278 @default.
- W4220684802 creator A5021880262 @default.
- W4220684802 creator A5023492006 @default.
- W4220684802 creator A5025429128 @default.
- W4220684802 creator A5043422475 @default.
- W4220684802 creator A5054678559 @default.
- W4220684802 creator A5068935035 @default.
- W4220684802 creator A5069374360 @default.
- W4220684802 creator A5074222006 @default.
- W4220684802 creator A5088234024 @default.
- W4220684802 creator A5088311413 @default.
- W4220684802 date "2022-06-01" @default.
- W4220684802 modified "2023-10-18" @default.
- W4220684802 title "Optimal Active Anti-Thymocyte Globulin Exposure Associated with Minimum Risk of Virus Reactivation and Comparable Acute Graft-Versus-Host Disease Under Adult Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation" @default.
- W4220684802 cites W1536174937 @default.
- W4220684802 cites W1600612350 @default.
- W4220684802 cites W1891100112 @default.
- W4220684802 cites W1976959601 @default.
- W4220684802 cites W1977694646 @default.
- W4220684802 cites W1978195094 @default.
- W4220684802 cites W1983875682 @default.
- W4220684802 cites W1996893745 @default.
- W4220684802 cites W2010732369 @default.
- W4220684802 cites W2029070864 @default.
- W4220684802 cites W2037735193 @default.
- W4220684802 cites W2039334806 @default.
- W4220684802 cites W2057094244 @default.
- W4220684802 cites W2059249274 @default.
- W4220684802 cites W2061878111 @default.
- W4220684802 cites W2068220988 @default.
- W4220684802 cites W2080854406 @default.
- W4220684802 cites W2083572422 @default.
- W4220684802 cites W2086693026 @default.
- W4220684802 cites W2106847738 @default.
- W4220684802 cites W2111395979 @default.
- W4220684802 cites W2120504920 @default.
- W4220684802 cites W2127419842 @default.
- W4220684802 cites W2142800729 @default.
- W4220684802 cites W2156818997 @default.
- W4220684802 cites W2164885965 @default.
- W4220684802 cites W2209448786 @default.
- W4220684802 cites W2233354089 @default.
- W4220684802 cites W2252670258 @default.
- W4220684802 cites W2273156022 @default.
- W4220684802 cites W2300854716 @default.
- W4220684802 cites W2346966299 @default.
- W4220684802 cites W2491860663 @default.
- W4220684802 cites W2529062107 @default.
- W4220684802 cites W2554963778 @default.
- W4220684802 cites W2560686337 @default.
- W4220684802 cites W2575158420 @default.
- W4220684802 cites W2592665339 @default.
- W4220684802 cites W2595371676 @default.
- W4220684802 cites W2595681737 @default.
- W4220684802 cites W2602863752 @default.
- W4220684802 cites W2802999222 @default.
- W4220684802 cites W2903838510 @default.
- W4220684802 cites W2905204531 @default.
- W4220684802 cites W2921261683 @default.
- W4220684802 cites W2942563145 @default.
- W4220684802 cites W2967100498 @default.
- W4220684802 cites W2986071054 @default.
- W4220684802 cites W3001557001 @default.
- W4220684802 cites W3009881536 @default.
- W4220684802 cites W3036991015 @default.
- W4220684802 cites W3097603104 @default.
- W4220684802 cites W3097812220 @default.
- W4220684802 cites W3172965236 @default.
- W4220684802 cites W4206701836 @default.
- W4220684802 doi "https://doi.org/10.1016/j.jtct.2022.03.018" @default.
- W4220684802 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35314377" @default.
- W4220684802 hasPublicationYear "2022" @default.
- W4220684802 type Work @default.
- W4220684802 citedByCount "4" @default.
- W4220684802 countsByYear W42206848022022 @default.
- W4220684802 countsByYear W42206848022023 @default.
- W4220684802 crossrefType "journal-article" @default.
- W4220684802 hasAuthorship W4220684802A5005228021 @default.
- W4220684802 hasAuthorship W4220684802A5007161525 @default.
- W4220684802 hasAuthorship W4220684802A5007172784 @default.
- W4220684802 hasAuthorship W4220684802A5010465278 @default.
- W4220684802 hasAuthorship W4220684802A5021880262 @default.
- W4220684802 hasAuthorship W4220684802A5023492006 @default.
- W4220684802 hasAuthorship W4220684802A5025429128 @default.
- W4220684802 hasAuthorship W4220684802A5043422475 @default.
- W4220684802 hasAuthorship W4220684802A5054678559 @default.
- W4220684802 hasAuthorship W4220684802A5068935035 @default.
- W4220684802 hasAuthorship W4220684802A5069374360 @default.
- W4220684802 hasAuthorship W4220684802A5074222006 @default.
- W4220684802 hasAuthorship W4220684802A5088234024 @default.
- W4220684802 hasAuthorship W4220684802A5088311413 @default.
- W4220684802 hasBestOaLocation W42206848021 @default.
- W4220684802 hasConcept C120665830 @default.